Related Experiment Video
Updated: Jul 23, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
CYP1A2 is not required for 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced immunosuppression
R J Smialowicz1, D E Burgin, W C Williams
1Experimental Toxicology Division, National Health and Environmental Effects Research Laboratory, US Environmental Protection Agency, Research Triangle Park, NC 27711, USA. smialowicz.ralph@epa.gov
Abstract:
One of the most sensitive and reproducible immunotoxic endpoints of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure is suppression of the antibody response to sheep red blood cells (SRBCs) in mice. Immunosuppression occurs in concert with hepatomegaly and associated induction of several hepatic cytochrome P450 enzymes, including CYP1A2 which is responsible for the hepatic sequestration of TCDD. In this study, TCDD-induced immunosuppression was evaluated in C57BL/6N CYP1A2 (+/+) wild-type and compared with that of age-matched CYP1A2 (-/-) knockout and CYP1A2 (+/-) heterozygous female mice. Groups of mice were given a single gavage dose of 0, 0.03, 0.1, 0.3, 1.0, 3.0 or 10.0microg TCDD/kg, followed 7 days later by immunization with SRBCs. Serum was obtained 5 days after immunization and body, spleen, thymus and liver weights were measured. sheep red blood cell (SRBC) antibody titers were determined by an enzyme-linked immunosorbent assay (ELISA). Anti-SRBC titers were suppressed at 1.0, 1.0 and 0.3microg TCDD/kg for CYP1A2 (+/+), CYP1A2 (+/-), and CYP1A2 (-/-) mice, respectively, which indicated a three-fold increase in TCDD-induced immunosuppression for the CYP1A2 (-/-) mice. This increase in TCDD-induced immunosuppression may be due to the inability of CYP1A2 (-/-) mice to sequester TCDD in the liver leading to a higher dose to the immune system. In CYP1A2 (+/+) mice, a dose of 3.0microg TCDD/kg was sufficient to increase the liver weight, while in CYP1A2 (-/-) mice no increase in liver weight was observed. Application of analysis of variance and dose-response modeling approaches indicate that there is little evidence that the immunosuppression dose-response curves, for the three strains, differ in the lower part of the dose-response range. Thus, CYP1A2 is not required for TCDD-induced immunosuppression in the mouse.
Insights
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure suppresses antibody responses in mice. CYP1A2 enzyme is not required for this TCDD-induced immunosuppression, as shown by studies comparing wild-type and knockout mice.
Area of Science:
- Immunotoxicology
- Environmental Toxicology
- Pharmacogenetics
Background:
- 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a potent environmental toxicant.
- Suppression of antibody response to sheep red blood cells (SRBCs) is a sensitive immunotoxic endpoint of TCDD exposure.
- Hepatic cytochrome P450 enzymes, including CYP1A2, are involved in TCDD metabolism and sequestration.
Purpose of the Study:
- To investigate the role of CYP1A2 in TCDD-induced immunosuppression.
- To compare the effects of TCDD on antibody responses in wild-type, heterozygous, and knockout CYP1A2 mice.
Main Methods:
- Groups of C57BL/6N mice (CYP1A2 +/+, +/-, and -/-) were administered single oral doses of TCDD.
- Mice were immunized with SRBCs, and antibody titers were measured using ELISA.
- Body, spleen, thymus, and liver weights were recorded.
Main Results:
- TCDD suppressed anti-SRBC titers in all mouse strains.
- CYP1A2 (-/-) mice exhibited a three-fold increase in immunosuppression sensitivity compared to wild-type mice.
- Liver weight increases, observed in wild-type mice at higher TCDD doses, were absent in CYP1A2 (-/-) mice.
Conclusions:
- CYP1A2 is not essential for TCDD-induced immunosuppression.
- The inability of CYP1A2 (-/-) mice to sequester TCDD in the liver may lead to increased systemic exposure and heightened immunosuppression.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

